Z Squared (ZSQR) risk factors

34 risks, 1 reworded since the prior year. Risk section changes are minimal, featuring only a reworded disclosure on Nasdaq listing requirements for risk 31.

34 risks. Z Squared faces substantial going concern doubt with minimal cash, negative cash flows, and no bank credit lines. Development heavily depends on clinical trials, regulatory approvals, and third-party intellectual property licenses. The company relies on key personnel like CEO David Mehalick and lacks independent market studies for its business plan.